Clinical Trials Browser

NIH × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 90 days × Clear all

NCT05724108 2026-03-19

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Phase 2 Active not recruiting

Neuroendocrine Tumors

NCT02466971 2026-03-18

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers

Phase 3 Active not recruiting

450 enrolled 11 charts

Uterine Cervical Neoplasms, Vaginal Neoplasms

NCT04494113 2026-03-18

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Phase EARLY_PHASE1 Active not recruiting

Endometrial Serous Adenocarcinoma

NCT06860594 2026-03-18

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

Phase 1 Recruiting

Astrocytoma, Glioblastoma, Lymphoma, Follicular

NCT04234568 2025-12-22

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors

Phase 1 Active not recruiting

31 enrolled 16 charts

Neuroendocrine Tumors